UCB revs up its gene therapy drive with Handl acquisition
pharmaphorum
NOVEMBER 12, 2020
UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.
Let's personalize your content